NCT00249145 – Risperidone in the Treatment of Behavioral Disturbances in Demented Patients: an International, Multicenter, Placebo-controlled, Double-blind, Parallel-group Trial Using Haloperidol as Internal Reference Posted on March 31, 2016 by tsuperadmin -
NCT00249236 – The Efficacy And Safety Of Flexible Dosage Ranges Of Risperidone Versus Placebo In The Treatment Of Manic Or Mixed Episodes Associated With Bipolar I Disorder Posted on March 31, 2016 by tsuperadmin -
NCT00261508 – Efficacy And Safety Of Risperidone In The Treatment Of Children With Autistic Disorder And Other Pervasive Developmental Disorders: A Canadian, Multicenter, Double-Blind, Placebo-Controlled Study Posted on March 31, 2016 by tsuperadmin -
Risperidone in the treatment of behavioural disturbances in patients with Alzheimer’s dementia: a double-blind placebo-controlled trial Posted on March 31, 2016 by tsuperadmin -
NCT00249158 – Risperidone in the Treatment of Behavioural and Psychological Signs and Symptoms in Dementia (BPSSD): a Multicentre, Double-blind, Placebo-controlled Parallel-group Trial Posted on March 31, 2016 by tsuperadmin -
NCT00378092 – A Prospective Study of the Clinical Outcome Following Treatment Discontinuation After Remission in First-Episode Schizophrenia Posted on September 16, 2015 by tsuperadmin -
NCT00253162 – The Efficacy And Safety Of Flexible Dose Ranges Of Risperidone Versus Placebo Or Haloperidol In The Treatment Of Manic Episodes Associated With Bipolar I Disorder Posted on August 10, 2015 by tsuperadmin -
NCT00216580 – An Open-label Trial of Risperidone Long-acting Injectable in the Treatment of Subjects With Recent Onset Psychosis Posted on August 3, 2015 by tsuperadmin -
NCT00216476 – CONSTATRE: Risperdal® Consta® Trial of Relapse Prevention and Effectiveness Posted on August 3, 2015 by tsuperadmin -
NCT00249132 – A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients Posted on July 16, 2015 by tsuperadmin -